Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study-Reference-Cited by-同舟云学术

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Published:2021-11 Issue:11 Volume:8 Page:e679-e689
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Jaeger Hans,Overton Edgar T,Richmond Gary,Rizzardini Giuliano,Andrade-Villanueva Jaime Federico,Mngqibisa Rosie,Hermida Antonio Ocampo,Thalme Anders,Belonosova Elena,Ajana Faïza,Benn Paul D,Wang Yuanyuan,Hudson Krischan J,Español Carlos Martín,Ford Susan L,Crauwels Herta,Margolis David A,Talarico Christine L,Smith Kimberly Y,van Eygen Veerle,Van Solingen-Ristea Rodica,Vanveggel Simon,Spreen William R

Funder

Janssen Research and Development LLC

ViiV Healthcare UK

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference25 articles.

1. Zidovudine approved by FDA for treatment of AIDS;Clin Pharm,1987

2. The end of AIDS: HIV infection as a chronic disease;Deeks;Lancet,2013

3. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals;AIDS,2010

4. The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11;Lesko;Int J Epidemiol,2016

5. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease;Murphy;Ann Intern Med,2001

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV;HIV RES CLIN PRACT;2024

2. Pittsburgh Sleep Quality Index (PSQI) Changes in Virologically Suppressed People Living with HIVSwitching to Long-Acting Cabotegravir and Rilpivirine;Biomedicines;2024-09-02

3. Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view;Journal of Antimicrobial Chemotherapy;2024-08-14

4. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South;AIDS Research and Human Retroviruses;2024-07-16

5. Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07